Sionna IPO Grosses $191m To Compete With Vertex In CF
NBD1 Stabilizers Are Add-Ons To CFTR Modulators
Sionna essentially doubled its cash on hand with its initial public offering to go up against a formidable competitor in cystic fibrosis with novel medicines applicable to a broad population.
